**Name of Journal: *World Journal of Hepatology***

**Manuscript NO: 32136**

**Manuscript Type: Minireviews**

**Risk factors and outcomes associated with alcohol relapse after liver transplantation**

Jane Lim *et al.* Alcohol relapse after liver transplantation for alcohol liver disease

**Jane Lim, Michael P Curry, Vinay Sundaram**

**Jane Lim,** Department of Medicine, Cedars Sinai Medical Center, Los Angeles, CA 90048, United States

**Michael P Curry,** Department of Medicine, Beth Israel Deaconess Medical Center, Boston, MA 02215, United States

**Vinay Sundaram,** Division of Gastroenterology and Comprehensive Transplant Center, Cedars-Sinai Medical Center, Los Angeles, CA 90048, United States

**Author contributions:** Lim J wrote the manuscript and generated the tables; Sundaram V designed the aim of the article and contributed to the writing and editing; Curry M provided guidance on the aim of the article and contributed to editing.

**Conflict-of-interest Statement:** There is no conflict of interest associated with any of the senior authors or other coauthors who contributed their efforts in this manuscript.

**Open-Access:** This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attrition Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

**Manuscript source:** Invited manuscript

**Correspondence to:** **Vinay Sundaram, MD, MSc,** Assistant Medical Director, Liver Transplantation, 8900 Beverly Blvd, Suite 250, Los Angeles, CA 90048, United States. [vinay.sundaram@cshs.org](mailto:Vinay.Sundaram@cshs.org)

**Telephone:** +1-310-4236000

**Fax:** +1-310-4230849

**Received:** December 27, 2016

**Peer-review started:** December 27, 2016

**First decision:** February 4, 2017

**Revised:** March 7, 2017

**Accepted:** April 23, 2017

**Article in press:**

**Published online:**

**Abstract**

Alcoholic liver disease (ALD) is the second most common indication for liver transplantation (LT) in the United States and Europe. Unlike other indications for LT, transplantation for ALD may be controversial due to the concern for alcohol relapse and non-compliance after LT. However, the overall survival in patients transplanted for ALD is comparable or higher than in patients transplanted for other etiologies of liver disease. While the rate of alcohol use after liver transplantation does not differ among various etiologies of liver disease, alcohol relapse after transplantation for ALD has been associated with complications such as graft rejection, graft loss, recurrent alcoholic cirrhosis and reduced long-term patient survival. Given these potential complications, our review aimed to discuss risk factors associated with alcohol relapse and the efficacy of various interventions attempted to reduce the risk of alcohol relapse. We also describe the impact of alcohol relapse on post-transplant outcomes including graft and patient survival. Overall, alcohol liver disease remains an appropriate indication for liver transplantation, and long-term mortality in this group of patients is primarily attributed to cardiovascular disease or de novo malignancies rather than alcohol related hepatic complications, among those who relapse.

**Key words:** Cirrhosis; Relapse prevention; Recidivism

**© The Author(s) 2017.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Core tip:** There are no established risk factors or scoring systems to predict alcohol relapse after transplantation for alcoholic liver disease. Studies regarding the “6-month rule” demonstrated heterogeneous findings, suggesting that this rule is not a reliable predictor of relapse. Comorbid psychiatric conditions, lack of social support, and tobacco use are consistently associated with alcohol relapse. Scoring systems have been proposed, but have not been validated. Alcohol relapse may be associated with graft rejection and graft loss, though reduction in long-term survival may be attributed to cardiovascular disease and de-novo malignancies rather than alcohol-related hepatic complications.

Lim J, Curry M, Sundaram V. Risk factors and outcomes associated with alcohol relapse after liver transplantation. *World J Hepatol* 2017; In press

**INTRODUCTION**

Alcohol use disorder (AUD) affects nearly 10% of the general population in both the United States (US) and Europe and is one of the most frequent causes of liver cirrhosis in the Western world[1]. After Hepatitis C virus (HCV) infection, alcoholic liver disease (ALD) is the second most common indication for liver transplantation (LT) in the US and Europe[2,3]. According to the OPTN/SRTR 2015 annual report, 21% of liver transplantation was for alcoholic liver disease[4].

Unlike other indications for LT, transplantation for ALD may be controversial because of the concern regarding relapse and medication non-compliance after transplantation[5]. The exact proportion of ALD patients who drink alcohol after LT is unclear and is reported to range anywhere between 7%-95%[6-8]. The broad range of percentages reported in the literature is because there are no standardized definitions for alcohol relapse[6-8]. Interestingly, the rate of alcohol use after LT does not differ between patients transplanted for other etiologies of liver disease, though recipients transplanted for ALD tend to drink in greater quantities[9,10]. In terms of patterns of alcohol use, there are varying frequencies given the different definitions and follow-up periods, but in general approximately 12%-33% of liver recipients for ALD relapse to abusive or harmful amounts of drinking[11-14] and 6%-26% relapse to occasional slips after transplantation[12,14,15]. Furthermore, the overall survival rate for patients transplanted for ALD is comparable or higher than those of patients transplanted for non-ALD[2,3,10,16]. Still, separate studies have identified harmful and excessive amounts of alcohol use to be associated with increased rates of graft rejection and failure[10,15,17-19]. Due to these potential adverse complications, our aim was to discuss risk factors associated with alcohol relapse after transplantation, the efficacy of interventions attempted to prevent relapse, and the post-transplant outcomes associated with alcohol relapse[5].

***Definitions***

There are no standardized definitions or classification criteria to describe alcohol consumption after transplantation. Terms that have been used in the literature include recidivism or relapse[7,15-17,19]. Quantification of alcohol consumption after LT can also be described using terms such as abstinence, occasional slip, harmful drinking and excessive drinking, though the definition of these terms are variable (Table 1)[8,20,21]. Lucey *et al*[22] defines harmful drinking as consumption of 4 or more drinks in one day or drinking for 4 or more days in succession, whereas a slip is defined as consumption of a limited amount of alcohol, followed by immediate measures to re-establish abstinence. De Gottardi *et al*[11] defined harmful drinking as alcohol consumption greater than 40 grams per day that was associated with the presence of alcohol-related damage, such as histologic features of alcoholic liver injury on biopsy. The Diagnostic and Statistical Manual of Mental Disorders Version IV (DSM IV) defined alcohol abuse as meeting one of the following criteria during a 12 month period: use which causes failure to fulfill major role obligations at work, school or home, use which causes a hazardous situation, use which causes legal problems or use continuing in the setting of recurrent social or interpersonal problems[23,24]. Faure’s study used the World Health Organization definition where excessive alcohol consumption was > 20 g and > 30 g per day for women and men[10].

***“The 6 mo rule”***

Many centers require 6 months of abstinence to be listed for liver transplantation. The 6 mo rule has two presumed purposes: to allow patients to recover from their liver disease and preclude the need for liver transplantation and to identify patients who are likely to remain abstinent after liver transplantation[1]. Nonetheless, there are conflicting findings as to whether this length of abstinence is needed to reduce the risk of relapse[11,25-27]. There have been several studies which have found that duration of abstinence less than 6 months is associated with alcohol use and harmful drinking[11,28,29]. Additionally, Tandon et al calculated that for every additional month of pre-LT abstinence there was a 5% decrease in the adjusted relapse rates[30]. This is contrasted by other studies that have shown that the 6-month rule is not a strong indicator of future drinking[26,27,31]. Based on the conflicting outcomes, the 6-month rule may not reliably predict post-transplant relapse.

Furthermore, achieving 6 months of abstinence is not always feasible, particularly for patients with severe alcoholic hepatitis that is refractory to treatment[32,33]. In fact, certain professional societies suggest that the 6-month rule should be not required in patients where the expected mortality of the disease would not allow for a 6-month waiting period[1,18,34]. Additionally, survival outcomes are superior among patients with severe alcoholic hepatitis that is refractory to corticosteroids and subsequently undergo OLT, as compared to those receiving standard of care[34-37]. As demonstrated by Mathurin *et al*[34]patients with severe alcoholic hepatitis who underwent OLT had a significantly greater cumulative 6 mo survival of 77% compared to 23% for controls who did not receive transplantation (*P* < 0.001).

**PATIENT FACTORS ASSOCIATED WITH RELAPSE**

***Age***

Like the 6-month rule, age has an inconsistent association with alcohol relapse after LT. A few studies have found that younger age is associated with alcohol relapse after LT and that the category of patients that relapsed were significantly younger compared to those that did not[14,26,38]. One study found that age < 45 years was associated with increased risk of relapse and another found an association between relapse and age < 40 years[15,38]. These findings are contrasted by other studies that found no association between age and alcohol relapse[8,27]. Furthermore, two larger studies determined that age is not an independent risk factor associated with alcohol relapse[11,15]. Based on the heterogeneity of these findings, we believe that age is not a reliable predictor of risk of alcohol relapse.

***Social support***

Lack of social support is an extrinsic factor that has consistently been associated with an increased risk of relapse for patients transplanted for ALD[13,15,31,39]. ALD patients who resumed alcohol use post-LT were more likely to be divorced or separated from their partners compared to those that remained abstinent, and multiple studies found that the lack of a spouse or life partner is a predictor of alcohol relapse[8,13,15,31]. One study also suggested that marriage is protective against binge drinking[13]. Therefore, it is important to ensure that patients with ALD have a strong support system during LT evaluation.

***Comorbid psychological conditions***

The presence of psychiatric comorbidities or previous diagnosis of a mental illness has been found to be an important intrinsic risk factor for increased risk of relapse after LT[11,13,31]. Multivariate analysis showed that a pre-LT diagnosis of a psychiatric disorder (anxiety or depressive disorder) at the time of listing was independently associated with a significantly increased risk of harmful levels of alcohol relapse, which is defined as consumption of greater than 40 grams per day[11]. Another study also determined that a prior diagnosis of a mental illness was significantly associated with harmful drinking, which was defined in her study as consumption of greater than 140 grams of ethanol per week[31]. Furthermore, prior treatment for co-morbid psychiatric disorders is a potential risk factor for alcohol relapse[40]. Evaluation for comorbid psychiatric conditions during the LT evaluation period may potentially help identify ALD patients that are at higher risk of both alcohol relapse and harmful drinking after transplantation.

***Employment***

In a cross-sectional study of organ transplant patients, only 37.5% of liver transplant patients were employed post-transplant[41]. Furthermore, among liver transplant recipients, those transplanted for ALD are significantly less likely to be employed both before and after transplant compared to transplant recipients for non-ALD[9]. A total of 29% of transplant recipients with ALD and 59% of those with non-ALD worked pre-transplantation, versus 33% of those with ALD versus 80% of non-ALD at 3 years post-transplantation (*P* < 0.00001)[9]. Furthermore, ALD patients that were previously employed were less likely to return to work compared to patients transplanted for non-ALD[8]. Despite the low proportion of ALD patients that work pre and post-transplant, employment status does not appear to be significantly associated with the risk of alcohol relapse after transplantation[8,26,27,31].

***Cigarette smoking***

Studies have found cigarette smoking to be associated with alcohol relapse after transplant for alcoholic cirrhosis[17,31,40,42]. Kelly *et al*[31] demonstrated in univariate analysis that pre-transplant tobacco use was a predictor of harmful alcohol drinking in the post-transplant period. This was not a significant finding when subjects were divided into no smoking, prior smoking or active smoking categories[31]. Additionally, ALD patients who drank both occasionally and heavily after LT were more likely to be smokers compared to those who remained abstinent[17]. Independent of alcohol relapse, cigarette smoking is an important risk factor for recipient morbidity and mortality[20,31,43,44]. Long-term consequences of cigarette smoking include hepatic artery thrombosis, cardiovascular disease and new onset malignancy of the aerodigestive tract[43,44]. History of tobacco use was also found to be associated with poorer survival after LT from cardiovascular disease or de novo non-hepatic cancer[20,31,43,44].

***Noncompliance with clinic visits***

Egawa *et al*[40] found noncompliance with clinic visits after LT, defined as 3 absences without notice, to be associated with both alcohol relapse and harmful drinking. In the study population, most patients underwent living donor liver transplantation, due to scarcity of deceased donors in Japan[40]. Furthermore, a cross-sectional study found that those who missed clinic appointments had lower adherence to immunosuppressive medications after liver transplant for any etiology (*P* < 0.001). In the study, non-adherence to immunosuppressive medications was liberally defined as any missed doses of transplant medications[45]. This finding is significant because strict adherence to immune suppressant agents is a very important factor in long-term outcome after liver transplant[46]. In multivariate analysis, missing physician appointments was the only independent factor associated with non-adherence to immune suppressants. Survey respondents who missed clinic visits were more than 4.7 times as likely to be non-adherent with immune suppressants compared to those who did not miss clinic visits (OR = 4.7, 95%CI: 1.5-14.7, *P* = 0.008 [45].

***HCV infection***

HCV infection and ALD often co-exist and approximately 8%-10% of liver transplantation performed was for mixed HCV and ALD cirrhosis[47]. Aguilera *et al*[48] compared post-transplantation outcomes among patients transplanted for alcoholic cirrhosis, mixed alcoholic cirrhosis and HCV and HCV alone. Interesting, there was no significant difference in rate of alcohol relapse between the mixed HCV and alcoholic cirrhosis group (8%) and the alcoholic cirrhosis group (18%). Alcohol relapse also does not affect liver histology or liver functions tests differently in recipients with concomitant HCV *vs* ALD alone. Additionally, rates of rejection and graft loss were not significantly different between the mixed HCV and ALD and ALD groups. While recurrence of HCV is a major cause of reduced survival in patients transplanted for HCV cirrhosis, 5-year survival was comparable between the mixed HCV and ALD group (73%) and alcoholic cirrhosis group (76%)[49,50]. Though further studies are warranted, based on these studies, presence of HCV does not appear to result in greater risk of alcohol relapse or worse post-transplantation outcomes.

***Scoring systems to predict alcohol relapse***

The two main scoring systems in the literature for alcohol relapse after LT are the High Risk Alcoholism Relapse (HRAR) Scale and the Alcohol Relapse Risk assessment (ARRA). The High Risk Alcoholism Relapse Scale was designed and piloted in the male veteran population and consists of 3 variables: duration of heavy drinking, number of drinks per day and number of prior alcoholism inpatient treatment experiences[51]. Each item is scored 0-2 and possible score ranges from 0 to 6. A HRAR score greater than 3 is associated with high risk of alcohol relapse[11].

The HRAR Scale has yet to be validated and thus far two studies did not find the HRAR score to be associated with post-OLT alcohol use[40,52]. In terms of the Alcohol Relapse Risk Assessment (ARRA), this tool found 9 domains to be significantly predictive of alcohol relapse. This scoring system includes both intrinsic and extrinsic risk factors of alcohol relapse. The intrinsic factors include low motivation for alcohol treatment and poor stress management skills. The extrinsic factors include limited social support, engagement in social activities with exposure to alcohol and lack of nonmedical behavioral consequences. The remaining factors are absence of hepatocellular carcinoma, dependence on tobacco and ongoing alcohol use after diagnosis of liver disease. Groups in ARRA III and IV (with 4-6 and 7-9 out the 9 factors) had significantly higher rates of alcohol relapse and were more likely to return to pre-transplant levels of drinking[39]. The ARRA scale has not been validated by other studies.

The Stanford Integrated Psychosocial Assessment for Transplant (SIPAT) was developed from a comprehensive literature review of psychosocial factors found to predict outcomes in liver, lung and heart transplant patients[53]. The SIPAT has been evaluated by one prospective study in liver, lung, kidney and heart transplant recipients. While mortality and organ failure was not associated with SIPAT scores, secondary medical and psychosocial outcomes such as rejection episodes, hospitalizations, infections and psychosocial decompensation were predicted by SIPAT[54]. The SIPAT has not yet been studied separately in liver transplant patients. In conclusion, there are no validated scoring systems to predict risk of alcohol relapse after LT at this time.

**INTERVENTIONS TO PREVENT RELAPSE**

***Relapse prevention and psychosocial therapy***

Studies have been conducted regarding relapse prevention before and after OLT. Erim *et al*[55] conducted a study that demonstrated that patients who received 6 months of pre-LT psycho-educational therapy had significantly less alcohol recidivism during the pre-transplant waiting period. Bjornsson *et al*[8] evaluated the effectiveness of active addiction treatment prior to transplant and demonstrated that active addiction treatment during the pre-LT period may reduce the risk of relapse after LT by more than 50% (from 48% to 22%). In the study, 19 out of 40 (48%) patients transplanted before the start of structured management had resumed alcohol compared to 13 (22%) out of 58 after this intervention that did not (*P* = 0.002). No treatment was offered in the post-operative period. In a retrospective study, Addolorato *et al*[25] evaluated the use of an alcohol addiction unit (AAU) that was integrated within the transplant center. Post-LT patients either followed up with addiction specialist at the transplant center or were offered addiction counseling by a provider outside the transplant unit. Patients who followed up in the AAU received multimodal treatment with counseling and pharmacologic treatment. Counseling involved 30-minute sessions that emphasized craving evaluation and identification of risk factors for alcohol relapse. Out of 92 cirrhotic liver transplant recipients the alcohol relapse rate was remarkably lower in recipients managed by the alcohol addiction unit within the transplant center (16.45%) compared to patients managed by psychiatrist not affiliated to liver transplant units (35.1%).

Rodrigue *et al*[56] found that patients who had received substance abuse treatment before LT did not differ in alcohol relapse compared to patients who did not (30% *vs* 39%, *P* = 0.20). Interestingly, he discovered that patients who received substance abuse treatment both before and after transplant had significantly lower rates of alcohol relapse (16% *vs* 41%) compared to patients who received substance abuse treatment only before transplant (45%) or those who did not receive any substance abuse treatment (41%). While more studies are needed to evaluate relapse prevention strategies, follow-up with addiction specialists integrated with a transplant unit and a combination of pre and post-transplant interventions may be more efficacious[56].

***Pharmacological interventions***

Several medications are approved for alcohol dependence, but only baclofen has been studied in a randomized control trial (RCT) in patients with alcoholic cirrhosis[57,58]. Baclofen is a gamma amino butyric acid (GABAb) receptor agonist that works by reducing craving for alcohol. In a RCT, a total of 84 patients with both alcohol use dependence and liver cirrhosis were randomized to receive baclofen 10 milligrams (mg) three times daily or placebo for 12 weeks. Baclofen demonstrated significant efficacy in promoting alcohol abstinence and reducing alcohol relapse. There were no serious side effects reported and no patient discontinued the medication during the study[58]. Furthermore, the baclofen study group displayed a significant decrease in alanine aminotransferase (ALT), gamma-glutamyl transferase (GGT), bilirubin and international normalized ratio (INR) values compared to placebo. It is theorized that the improvement in liver function tests was due to the significant reduction of alcohol intake in the baclofen group[58]. Baclofen has yet to be studied in the decompensated patient and post-LT population.

Other drugs that are currently approved for alcohol dependence include disulfiram, naltrexone and acomprosate, however these have not been studied in the post-transplant population. Additionally, both disulfiram and naltrexone are not ideal options for ALD patients due to their risk of hepatotoxicity[59-62].

Disulfiram was one of the first drugs approved for alcohol dependence and is an irreversible inhibitor of aldehyde dehydrogenase (ALD)[60,63,64]. If alcohol is consumed while taking disulfiram, acetaldehyde levels will increase and result in a disulfiram reaction of hypotension, flushing, nausea and vomiting that may deter patients from drinking alcohol[63]. Naltrexone is an antagonist of κ-and μ-opioid receptors and increases dopamine release in the mesolimbic system, which may help reduce alcohol craving[65]. The long acting intramuscular formulation of naltrexone may be less hepatotoxic because it does not undergo first pass metabolism by the liver, but both the oral and intramuscular formulations currently carry a black-box warning for liver damage[59,62]. Another anti-craving medication, acamprosate, is an N-methyl-D-aspartate glutamate receptor antagonist with an unclear mechanism of action. It is not metabolized by the liver and is not associated with liver toxicity[66]. Furthermore, a preliminary study suggested that 1 d of administration was well tolerated in patients with Child-Pugh class A and B cirrhosis[67]. More studies are needed to establish its efficacy in patients transplanted for alcohol liver disease and its safety profile with repeated administration.

Other promising pharmacologic agents to reduce alcohol relapse include topiramate and ondansetron[59]. Topiramate is only partially metabolized by the liver (22%) and is primarily excreted by the kidneys[68]. Ondansetron is a serotonin (5-HT3) receptor antagonist that is thought to downregulate dopaminergic neurons, reducing the reward pathway for alcohol[69]. It has been shown to be more effective than placebo in increasing total days of abstinence and percentage of abstinent days[70]. Its major side effect was QT prolongation, which was a dose related complication[71]. More studies are needed to evaluate the efficacy and safety profiles of topiramate and ondandestron in post-liver transplant patients[68,70].

***Consequences of alcohol use on allograft outcomes***

Graft rejection, graft loss and recurrent alcohol cirrhosis are feared complications of alcohol relapse after transplant for ALD patients. It has been suggested that alcohol relapse may lead to reduced compliance associated with a significantly increased graft rejection rate[14,17,72]. Pageaux *et al*[17] demonstrated that that while there was no significant difference in graft rejection rates between abstinent, occasional drinkers or heavy drinkers, the rejection episodes observed in the heavy drinker category were related to poor compliance to immunosuppressant medications. Therefore, alcohol consumption after LT may be a marker of medication non-adherence and can potentially predict risk of graft rejection. Overall, graft loss from recurrence of ALD is uncommon, but multiple studies have shown that alcohol use after transplant is associated with an increased risk of graft loss and advanced allograft fibrosis[14,17,72-74]. In a study by Rice *et al*[14] any alcohol relapse increased the risk of graft failure, but upon subdivision by drinking pattern, a single slip or intermittent relapse was not associated with graft failure, but continuous heavy drinking was significantly associated with decreased graft survival. In terms of histopathology, patients with alcohol relapse were more likely to have advanced fibrosis (stage 3 or higher) compared to those that remained abstinent[14]. In the study, 20.8% of patients had a single slip and 33.3% of patients relapsed to continuous heavy drinking[14]. Multiple studies have demonstrated that patients with heavy post-transplant drinking were more likely to have more fatty changes and severe fibrosis[17,48]. Still, these histologic findings may also be explained by nonalcoholic hepatitis, given the fact that metabolic syndrome is common among post-LT patients[75].

***Survival***

The overall survival rate of patients transplanted for ALD is comparable or higher than the survival rates of patients transplanted for other etiologies[2,3,10,16]. According to an article by Dumortier, survival after liver transplant for ALD is 92.6% at 1 year, 88.5% at 3 years and 84.3% at 5 years and 73.4 at 10 years, which is comparable to that of patient’s transplanted for other etiologies cirrhosis[20]. While occasional slips are not associated with reduced survival, relapse to abusive or harmful levels of drinking is associated with increased mortality in ALD patients[15]. Interestingly, mortality after LT for ALD is rarely due to recurrent alcoholic cirrhosis. According to DuMortier et al, only 3% of deaths were related to alcohol cirrhosis after transplant and only 0.7% of the patients transplanted for alcoholic cirrhosis died from recurrent alcoholic cirrhosis[20]. This finding was consistent with another study where only 1 (1%) deaths was related to alcohol relapse whereas the majority of deaths were attributed to cancer[27]. Bjornsson *et al*[8] also found that deaths in the group of patients that resumed alcohol use were not directly related to alcohol use. While alcohol use itself does not reduce post-transplant survival, recurrent alcoholic cirrhosis does significantly reduced post-transplant survival. One-, 5-, 10-, and 15-year survival was 100, 87.6, 49.7, and 21.0%, respectively, for patients with recurrent alcoholic cirrhosis versus 100, 89.4, 69.9, and 41.1%, respectively, for the patients without recurrent alcoholic cirrhosis (*P* < 0.001)[76]. Furthermore, Cuadrado *et al*[72] found no difference in 1 or 5 year survival in those who were abstinent versus those with alcohol relapse, but the study did find a remarkably worse 10 year survival in patients with alcohol use of more than 30 grams/day (45.1% *vs* 85.5%). This difference in long-term mortality did not appear to be related to liver failure, graft rejection, infection rate or metabolic disturbances, but was attributed to a higher frequency of deaths from de novo malignancy and cardiovascular events[72]. Therefore, the major long-term causes of mortality in patients transplanted for ALD appear to be due to cardiovascular disease and de novo malignancy rather than related to alcohol use[10,20,38,72,76].

**CONCLUSION**

Overall, ALD is a good indication for liver transplantation. Patients transplanted for ALD have comparable survival rates to patients transplanted for other etiologies of liver disease[2,3,10,16].

Based on this review article, consistent predictors of alcohol relapse include comorbid psychiatric conditions, social support and tobacco use[11,13,15,29,31,40,77,78]. While the 6-month rule is a common prerequisite for LT listing, it is not a reliable predictor of alcohol relapse[8,27,28]. It is also not feasible for some patients, particularly those with severe alcoholic hepatitis that is refractory to medical management[34]. Furthermore, scoring systems to predict relapse such as the HRAR and ARRA have been proposed but have yet to be validated by other studies.

Additionally, participation in an addiction unit integrated within a transplant center was found to be efficacious in reducing alcohol relapse after LT, but further studies are still needed to reproduce this finding[25]. Rodrigue *et al*[56] did not find that pre-LT treatment of substance abuse disorders to significantly impact relapse post-LT, but patients who received both pre-and post-transplant substance abuse treatment were significantly less likely to drink post-transplant. Therefore, continuous addiction treatment may play an important role in this population.

Multiple drugs have been approved for alcohol dependence, but the majority has not yet been studied in patients transplanted for ALD[57,58]. Baclofen appears to be the most promising pharmacologic agent in promoting abstinence post-transplant and was shown to have a good safety profile in patients with advanced liver disease. Further research is needed to determine whether baclofen can reduce alcohol relapse in ALD patients in the post-transplant period. Acomprasate, topiramate and ondansetron are also promising agents because of their lower risk of hepatotoxicity, but further research is needed[59,66,67].

Lastly, alcohol relapse is associated with increased rates of graft rejection[14,17,72]. This is thought to be due to the association between alcohol use and non-adherence to immunosuppressive agents[14,17,72]. While occasional slips do not impact graft loss, a harmful or excessive amount of alcohol use post-LT has been found to be associated with an increased rate of graft loss and advanced fibrosis[14,17,48]. Heavy drinkers were also noted to have more fatty changes and steatohepatitis compared to those who remained abstinent, though this finding may be confounded by nonalcoholic steatohepatitis[14,17,72,73,75]. Overall, survival in ALD patients is comparable or higher compared to those transplanted for other etiologies of liver disease[2,3,10,16]. Long-term survival at 10 years was found to be significantly lower in those that resumed alcohol use, but this was attributed to mortality from de novo malignancies and cardiovascular events rather than due to liver failure[72,75].

|  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| |  |  |  |  |  | | --- | --- | --- | --- | --- | | |  |  | | --- | --- | | **REFERENCES**  1 **European Association for the Study of Liver.** EASL clinical practical guidelines: management of alcoholic liver disease. *J Hepatol* 2012; **57**: 399-420 [PMID: 22633836 DOI: 10.1016/j.jhep.2012.04.004]  2 **Burra P**, Senzolo M, Adam R, Delvart V, Karam V, Germani G, Neuberger J. Liver transplantation for alcoholic liver disease in Europe: a study from the ELTR (European Liver Transplant Registry). *Am J Transplant* 2010; **10**: 138-148 [PMID: 19951276 DOI: 10.1111/j.1600-6143.2009.02869.x]  3 **United Network for Organ Sharing.** Available from: URL: http: //www.unos.org. 2016.  4 **Kim WR**, Lake JR, Smith JM, Skeans MA, Schladt DP, Edwards EB, Harper AM, Wainright JL, Snyder JJ, Israni AK, Kasiske BL. OPTN/SRTR 2015 Annual Data Report: Liver. *Am J Transplant* 2017; **17** Suppl 1: 174-251 [PMID: 28052604 DOI: 10.1111/ajt.14126]  5 **Lucey MR**, Connor JT, Boyer TD, Henderson JM, Rikkers LF. Alcohol consumption by cirrhotic subjects: patterns of use and effects on liver function. *Am J Gastroenterol* 2008; **103**: 1698-1706 [PMID: 18494835 DOI: 10.1111/j.1572-0241.2008.01837.x]  6 **Lim JK,** Keeffe EB. Liver transplantation for alcoholic liver disease: current concepts and length of sobriety. *Liver Transpl* 2004; **10** (10 Suppl 2): S31-38 [PMID 15382288 DOI: 10.1002/lt.20267]  7 **Pageaux GP**, Michel J, Coste V, Perney P, Possoz P, Perrigault PF, Navarro F, Fabre JM, Domergue J, Blanc P, Larrey D. Alcoholic cirrhosis is a good indication for liver transplantation, even for cases of recidivism. *Gut* 1999; **45**: 421-426 [PMID: 10446113]  8 **Björnsson E**, Olsson J, Rydell A, Fredriksson K, Eriksson C, Sjöberg C, Olausson M, Bäckman L, Castedal M, Friman S. Long-term follow-up of patients with alcoholic liver disease after liver transplantation in Sweden: impact of structured management on recidivism. *Scand J Gastroenterol* 2005; **40**: 206-216 [PMID: 15764153 DOI: 10.1080/00365520410009591]  9 **Bravata DM**, Olkin I, Barnato AE, Keeffe EB, Owens DK. Employment and alcohol use after liver transplantation for alcoholic and nonalcoholic liver disease: a systematic review. *Liver Transpl* 2001; **7**: 191-203 [PMID: 11244159 DOI: 10.1053/jlts.2001.22326]  10 **Faure S**, Herrero A, Jung B, Duny Y, Daures JP, Mura T, Assenat E, Bismuth M, Bouyabrine H, Donnadieu-Rigole H, Navarro F, Jaber S, Larrey D, Pageaux GP. Excessive alcohol consumption after liver transplantation impacts on long-term survival, whatever the primary indication. *J Hepatol* 2012; **57**: 306-312 [PMID: 22521352 DOI: 10.1016/j.jhep.2012.03.014]  11 **De Gottardi A**, Spahr L, Gelez P, Morard I, Mentha G, Guillaud O, Majno P, Morel P, Hadengue A, Paliard P, Scoazec JY, Boillot O, Giostra E, Dumortier J. A simple score for predicting alcohol relapse after liver transplantation: results from 387 patients over 15 years. *Arch Intern Med* 2007; **167**: 1183-1188 [PMID: 17563028 DOI: 10.1001/archinte.167.11.1183]  12 **Lucey MR**. Liver transplantation in patients with alcoholic liver disease. *Liver Transpl* 2011; **17**: 751-759 [PMID: 21567894 DOI: 10.1002/lt.22330]  13 **DiMartini A**, Day N, Dew MA, Javed L, Fitzgerald MG, Jain A, Fung JJ, Fontes P. Alcohol consumption patterns and predictors of use following liver transplantation for alcoholic liver disease. *Liver Transpl* 2006; **12**: 813-820 [PMID: 16528710 DOI: 10.1002/lt.20688]  14 **Rice JP**, Eickhoff J, Agni R, Ghufran A, Brahmbhatt R, Lucey MR. Abusive drinking after liver transplantation is associated with allograft loss and advanced allograft fibrosis. *Liver Transpl* 2013; **19**: 1377-1386 [PMID: 24115392 DOI: 10.1002/lt.23762]  15 **Pfitzmann R**, Schwenzer J, Rayes N, Seehofer D, Neuhaus R, Nüssler NC. Long-term survival and predictors of relapse after orthotopic liver transplantation for alcoholic liver disease. *Liver Transpl* 2007; **13**: 197-205 [PMID: 17205563 DOI: 10.1002/lt.20934]  16 **Lucey MR**, Schaubel DE, Guidinger MK, Tome S, Merion RM. Effect of alcoholic liver disease and hepatitis C infection on waiting list and posttransplant mortality and transplant survival benefit. *Hepatology* 2009; **50**: 400-406 [PMID: 19472315 DOI: 10.1002/hep.23007]  17 **Pageaux GP**, Bismuth M, Perney P, Costes V, Jaber S, Possoz P, Fabre JM, Navarro F, Blanc P, Domergue J, Eledjam JJ, Larrey D. Alcohol relapse after liver transplantation for alcoholic liver disease: does it matter? *J Hepatol* 2003; **38**: 629-634 [PMID: 12713874]  18 **Addolorato G**, Bataller R, Burra P, DiMartini A, Graziadei I, Lucey MR, Mathurin P, OʼGrady J, Pageaux G, Berenguer M. Liver Transplantation for Alcoholic Liver Disease. *Transplantation* 2016; **100**: 981-987 [PMID: 26985744 DOI: 10.1097/TP.0000000000001156]  19 **Rustad JK**, Stern TA, Prabhakar M, Musselman D. Risk factors for alcohol relapse following orthotopic liver transplantation: a systematic review. *Psychosomatics* 2015; **56**: 21-35 [PMID: 25619671 DOI: 10.1016/j.psym.2014.09.006]  20 **Dumortier J**, Guillaud O, Adham M, Boucaud C, Delafosse B, Bouffard Y, Paliard P, Scoazec JY, Boillot O. Negative impact of de novo malignancies rather than alcohol relapse on survival after liver transplantation for alcoholic cirrhosis: a retrospective analysis of 305 patients in a single center. *Am J Gastroenterol* 2007; **102**: 1032-1041 [PMID: 17313502 DOI: 10.1111/j.1572-0241.2007.01079.x]  21 **Lucey MR**. Liver transplantation for alcoholic liver disease. *Clin Liver Dis* 2007; **11**: 283-289 [PMID: 17606207 DOI: 10.1016/j.cld.2007.04.014]  22 **Lucey MR**. Liver transplantation for alcoholic liver disease: past, present, and future. *Liver Transpl* 2007; **13**: 190-192 [PMID: 17256778 DOI: 10.1002/lt.21014]  23 **Kotlyar DS**, Burke A, Campbell MS, Weinrieb RM. A critical review of candidacy for orthotopic liver transplantation in alcoholic liver disease. *Am J Gastroenterol* 2008; **103**: 734-43; quiz 744 [PMID: 18081918 DOI: 10.1111/j.1572-0241.2007.01691.x]  24 **American Psychiatric Association**. Diagnostic and statistical manual of mental disorders (DSM-IV), 4th Ed. American Psychiatric Association: Washington, DC, 1994: 181–183  25 **Addolorato G**, Mirijello A, Leggio L, Ferrulli A, D'Angelo C, Vassallo G, Cossari A, Gasbarrini G, Landolfi R, Agnes S, Gasbarrini A. Liver transplantation in alcoholic patients: impact of an alcohol addiction unit within a liver transplant center. *Alcohol Clin Exp Res* 2013; **37**: 1601-1608 [PMID: 23578009 DOI: 10.1111/acer.12117]  26 **Perney P**, Bismuth M, Sigaud H, Picot MC, Jacquet E, Puche P, Jaber S, Rigole H, Navarro F, Eledjam JJ, Blanc F, Larrey D, Pageaux GP. Are preoperative patterns of alcohol consumption predictive of relapse after liver transplantation for alcoholic liver disease? *Transpl Int* 2005; **18**: 1292-1297 [PMID: 16221161 DOI: 10.1111/j.1432-2277.2005.00208.x]  27 **Jauhar S**, Talwalkar JA, Schneekloth T, Jowsey S, Wiesner RH, Menon KV. Analysis of factors that predict alcohol relapse following liver transplantation. *Liver Transpl* 2004; **10**: 408-411 [PMID: 15004769 DOI: 10.1002/lt.20086]  28 **Osorio RW**, Ascher NL, Avery M, Bacchetti P, Roberts JP, Lake JR. Predicting recidivism after orthotopic liver transplantation for alcoholic liver disease. *Hepatology* 1994; **20**: 105-110 [PMID: 8020879]  29 **Karim Z**, Intaraprasong P, Scudamore CH, Erb SR, Soos JG, Cheung E, Cooper P, Buzckowski AK, Chung SW, Steinbrecher UP, Yoshida EM. Predictors of relapse to significant alcohol drinking after liver transplantation. *Can J Gastroenterol* 2010; **24**: 245-250 [PMID: 20431813]  30 **Tandon P**, Goodman KJ, Ma MM, Wong WW, Mason AL, Meeberg G, Bergsten D, Carbonneau M, Bain VG. A shorter duration of pre-transplant abstinence predicts problem drinking after liver transplantation. *Am J Gastroenterol* 2009; **104**: 1700-1706 [PMID: 19471253 DOI: 10.1038/ajg.2009.226]  31 **Kelly M**, Chick J, Gribble R, Gleeson M, Holton M, Winstanley J, McCaughan GW, Haber PS. Predictors of relapse to harmful alcohol after orthotopic liver transplantation. *Alcohol Alcohol* 2006; **41**: 278-283 [PMID: 16476764 DOI: 10.1093/alcalc/agh257]  32 **Mathurin P**, Bataller R. Trends in the management and burden of alcoholic liver disease. *J Hepatol* 2015; **62**: S38-S46 [PMID: 25920088 DOI: 10.1016/j.jhep.2015.03.006]  33 **Mathurin P**. Therapeutic management of alcoholic hepatitis. *Clin Res Hepatol Gastroenterol* 2015; **39** Suppl 1: S41-S45 [PMID: 26189979 DOI: 10.1016/j.clinre.2015.05.015]  34 **Mathurin P**, Moreno C, Samuel D, Dumortier J, Salleron J, Durand F, Castel H, Duhamel A, Pageaux GP, Leroy V, Dharancy S, Louvet A, Boleslawski E, Lucidi V, Gustot T, Francoz C, Letoublon C, Castaing D, Belghiti J, Donckier V, Pruvot FR, Duclos-Vallée JC. Early liver transplantation for severe alcoholic hepatitis. *N Engl J Med* 2011; **365**: 1790-1800 [PMID: 22070476 DOI: 10.1056/NEJMoa1105703]  35 **Im GY**, Kim-Schluger L, Shenoy A, Schubert E, Goel A, Friedman SL, Florman S, Schiano TD. Early Liver Transplantation for Severe Alcoholic Hepatitis in the United States--A Single-Center Experience. *Am J Transplant* 2016; **16**: 841-849 [PMID: 26710309 DOI: 10.1111/ajt.13586]  36 **Lee BP**, Chen PH, Haugen C, Hernaez R, Gurakar A, Philosophe B, Dagher N, Moore SA, Li Z, Cameron AM. Three-year Results of a Pilot Program in Early Liver Transplantation for Severe Alcoholic Hepatitis. *Ann Surg* 2017; **265**: 20-29 [PMID: 27280501 DOI: 10.1097/SLA.0000000000001831]  37 **Singal AK**, Bashar H, Anand BS, Jampana SC, Singal V, Kuo YF. Outcomes after liver transplantation for alcoholic hepatitis are similar to alcoholic cirrhosis: exploratory analysis from the UNOS database. *Hepatology* 2012; **55**: 1398-1405 [PMID: 22213344 DOI: 10.1002/hep.25544]  38 **Grąt M**, Lewandowski Z, Grąt K, Wronka KM, Krasnodębski M, Barski K, Zborowska H, Patkowski W, Zieniewicz K, Krawczyk M. Negative outcomes after liver transplantation in patients with alcoholic liver disease beyond the fifth post-transplant year. *Clin Transplant* 2014; **28**: 1112-1120 [PMID: 25059535 DOI: 10.1111/ctr.12427]  39 **Rodrigue JR**, Hanto DW, Curry MP. The Alcohol Relapse Risk Assessment: a scoring system to predict the risk of relapse to any alcohol use after liver transplant. *Prog Transplant* 2013; **23**: 310-318 [PMID: 24311394 DOI: 10.7182/pit2013604]  40 **Egawa H**, Nishimura K, Teramukai S, Yamamoto M, Umeshita K, Furukawa H, Uemoto S. Risk factors for alcohol relapse after liver transplantation for alcoholic cirrhosis in Japan. *Liver Transpl* 2014; **20**: 298-310 [PMID: 24470014 DOI: 10.1002/lt.23797]  41 **De Baere C**, Delva D, Kloeck A, Remans K, Vanrenterghem Y, Verleden G, Vanhaecke J, Nevens F, Dobbels F. Return to work and social participation: does type of organ transplantation matter? *Transplantation* 2010; **89**: 1009-1015 [PMID: 20147883 DOI: 10.1097/TP.0b013e3181ce77e5]  42 **Satapathy SK**, Eason JD, Nair S, Dryn O, Sylvestre PB, Kocak M, Vanatta JM. Recidivism in Liver Transplant Recipients With Alcoholic Liver Disease: Analysis of Demographic, Psychosocial, and Histology Features. *Exp Clin Transplant* 2015; **13**: 430-440 [PMID: 26450466]  43 **Watt KD**, Pedersen RA, Kremers WK, Heimbach JK, Charlton MR. Evolution of causes and risk factors for mortality post-liver transplant: results of the NIDDK long-term follow-up study. *Am J Transplant* 2010; **10**: 1420-1427 [PMID: 20486907 DOI: 10.1111/j.1600-6143.2010.03126.x]  44 **Lucey MR**, Terrault N, Ojo L, Hay JE, Neuberger J, Blumberg E, Teperman LW. Long-term management of the successful adult liver transplant: 2012 practice guideline by the American Association for the Study of Liver Diseases and the American Society of Transplantation. *Liver Transpl* 2013; **19**: 3-26 [PMID: 23281277 DOI: 10.1002/lt.23566]  45 **Lamba S**, Nagurka R, Desai KK, Chun SJ, Holland B, Koneru B. Self-reported non-adherence to immune-suppressant therapy in liver transplant recipients: demographic, interpersonal, and intrapersonal factors. *Clin Transplant* 2012; **26**: 328-335 [PMID: 21955028 DOI: 10.1111/j.1399-0012.2011.01489.x]  46 **Adam R**, Karam V, Delvart V, O'Grady J, Mirza D, Klempnauer J, Castaing D, Neuhaus P, Jamieson N, Salizzoni M, Pollard S, Lerut J, Paul A, Garcia-Valdecasas JC, Rodríguez FS, Burroughs A. Evolution of indications and results of liver transplantation in Europe. A report from the European Liver Transplant Registry (ELTR). *J Hepatol* 2012; **57**: 675-688 [PMID: 22609307 DOI: 10.1016/j.jhep.2012.04.015]  47 **Singal AK**, Guturu P, Hmoud B, Kuo YF, Salameh H, Wiesner RH. Evolving frequency and outcomes of liver transplantation based on etiology of liver disease. *Transplantation* 2013; **95**: 755-760 [PMID: 23370710 DOI: 10.1097/TP.0b013e31827afb3a]  48 **Burra P**, Mioni D, Cecchetto A, Cillo U, Zanus G, Fagiuoli S, Naccarato R, Martines D. Histological features after liver transplantation in alcoholic cirrhotics. *J Hepatol* 2001; **34**: 716-722 [PMID: 11434618]  49 **Aguilera V**, Berenguer M, Rubín A, San-Juan F, Rayón JM, Prieto M, Mir J. Cirrhosis of mixed etiology (hepatitis C virus and alcohol): Posttransplantation outcome-Comparison with hepatitis C virus-related cirrhosis and alcoholic-related cirrhosis. *Liver Transpl* 2009; **15**: 79-87 [PMID: 19109849 DOI: 10.1002/lt.21626]  50 **Forman LM**, Lewis JD, Berlin JA, Feldman HI, Lucey MR. The association between hepatitis C infection and survival after orthotopic liver transplantation. *Gastroenterology* 2002; **122**: 889-896 [PMID: 11910340]  51 **Yates WR**, Booth BM, Reed DA, Brown K, Masterson BJ. Descriptive and predictive validity of a high-risk alcoholism relapse model. *J Stud Alcohol* 1993; **54**: 645-651 [PMID: 8271799 DOI: 10.15288/jsa.1993.54.645]  52 **DiMartini A**, Magill J, Fitzgerald MG, Jain A, Irish W, Khera G, Yates W. Use of a high-risk alcohol relapse scale in evaluating liver transplant candidates. *Alcohol Clin Exp Res* 2000; **24**: 1198-1201 [PMID: 10968657 DOI: 10.1111/j.1530-0277.2000.tb02083.x]  53 **Maldonado JR**, Dubois HC, David EE, Sher Y, Lolak S, Dyal J, Witten D. The Stanford Integrated Psychosocial Assessment for Transplantation (SIPAT): a new tool for the psychosocial evaluation of pre-transplant candidates. *Psychosomatics* 2012; **53**: 123-132 [PMID: 22424160 DOI: 10.1016/j.psym.2011.12.012]  54 **Maldonado JR**, Sher Y, Lolak S, Swendsen H, Skibola D, Neri E, David EE, Sullivan C, Standridge K. The Stanford Integrated Psychosocial Assessment for Transplantation: A Prospective Study of Medical and Psychosocial Outcomes. *Psychosom Med* 2015; **77**: 1018-1030 [PMID: 26517474 DOI: 10.1097/PSY.0000000000000241]  55 **Erim Y**, Beckmann M, Tagay S, Beckebaum S, Gerken G, Broelsch CE, Senf W. [Stabilisation of abstinence by means of psychoeducation for patients with alcoholic liver disease awaiting liver transplantation]. *Z Psychosom Med Psychother* 2006; **52**: 341-357 [PMID: 17156604 DOI: 10.13109/zptm.2006.52.4.341]  56 **Rodrigue JR**, Hanto DW, Curry MP. Substance abuse treatment and its association with relapse to alcohol use after liver transplantation. *Liver Transpl* 2013; **19**: 1387-1395 [PMID: 24123780 DOI: 10.1002/lt.23747]  57 **Addolorato G**, Caputo F, Capristo E, Domenicali M, Bernardi M, Janiri L, Agabio R, Colombo G, Gessa GL, Gasbarrini G. Baclofen efficacy in reducing alcohol craving and intake: a preliminary double-blind randomized controlled study. *Alcohol Alcohol* 2002; **37**: 504-508 [PMID: 12217947 DOI: 10.1093/alcalc/37.5.504]  58 **Addolorato G**, Leggio L, Ferrulli A, Cardone S, Vonghia L, Mirijello A, Abenavoli L, D'Angelo C, Caputo F, Zambon A, Haber PS, Gasbarrini G. Effectiveness and safety of baclofen for maintenance of alcohol abstinence in alcohol-dependent patients with liver cirrhosis: randomised, double-blind controlled study. *Lancet* 2007; **370**: 1915-1922 [PMID: 18068515 DOI: 10.1016/S0140-6736(07)61814-5]  59 **Addolorato G**, Mirijello A, Leggio L, Ferrulli A, Landolfi R. Management of alcohol dependence in patients with liver disease. *CNS Drugs* 2013; **27**: 287-299 [PMID: 23456576 DOI: 10.1007/s40263-013-0043-4]  60 **Rosato V**, Abenavoli L, Federico A, Masarone M, Persico M. Pharmacotherapy of alcoholic liver disease in clinical practice. *Int J Clin Pract* 2016; **70**: 119-131 [PMID: 26709723 DOI: 10.1111/ijcp.12764]  61 **Eneanya DI**, Bianchine JR, Duran DO, Andresen BD. The actions of metabolic fate of disulfiram. *Annu Rev Pharmacol Toxicol* 1981; **21**: 575-596 [PMID: 7016017 DOI: 10.1146/annurev.pa.21.040181.003043]  62 **Garbutt JC**. Efficacy and tolerability of naltrexone in the management of alcohol dependence. *Curr Pharm Des* 2010; **16**: 2091-2097 [PMID: 20482515 DOI: 10.2174/138161210791516459]  63 **Swift R**. Emerging approaches to managing alcohol dependence. *Am J Health Syst Pharm* 2007; **64**: S12-S22 [PMID: 17322178 DOI: 10.2146/ajhp060644]  64 **Soyka M**, Rösner S. Emerging drugs to treat alcoholism. *Expert Opin Emerg Drugs* 2010; **15**: 695-711 [PMID: 20560783 DOI: 10.1517/14728214.2010.500811]  65 **Volpicelli JR**, Alterman AI, Hayashida M, O'Brien CP. Naltrexone in the treatment of alcohol dependence. *Arch Gen Psychiatry* 1992; **49**: 876-880 [PMID: 1345133 DOI: 10.1001/archpsyc.1992.01820110040006]  66 **Tolliver BK**, Desantis SM, Brown DG, Prisciandaro JJ, Brady KT. A randomized, double-blind, placebo-controlled clinical trial of acamprosate in alcohol-dependent individuals with bipolar disorder: a preliminary report. *Bipolar Disord* 2012; **14**: 54-63 [PMID: 22329472 DOI: 10.1111/j.1399-5618.2011.00973.x]  67 **Delgrange T**, Khater J, Capron D, Duron B, Capron JP. [Effect of acute administration of acamprosate on the risk of encephalopathy and on arterial pressure in patients with alcoholic cirrhosis]. *Gastroenterol Clin Biol* 1992; **16**: 687-691 [PMID: 1426825]  68 **Mozayani A**, Carter J, Nix R. Distribution of topiramate in a medical examiner's case. *J Anal Toxicol* 1999; **23**: 556-558 [PMID: 10517568 DOI: 10.1093/jat/23.6.556]  69 **Kenna GA**. Medications acting on the serotonergic system for the treatment of alcohol dependent patients. *Curr Pharm Des* 2010; **16**: 2126-2135 [PMID: 20482508 DOI: 10.2174/138161210791516396]  70 **Johnson BA**, Roache JD, Javors MA, DiClemente CC, Cloninger CR, Prihoda TJ, Bordnick PS, Ait-Daoud N, Hensler J. Ondansetron for reduction of drinking among biologically predisposed alcoholic patients: A randomized controlled trial. *JAMA* 2000; **284**: 963-971 [PMID: 10944641 DOI: 10.1001/jama.284.8.963]  71 **Kenna GA**, Zywiak WH, McGeary JE, Leggio L, McGeary C, Wang S, Grenga A, Swift RM. A within-group design of nontreatment seeking 5-HTTLPR genotyped alcohol-dependent subjects receiving ondansetron and sertraline. *Alcohol Clin Exp Res* 2009; **33**: 315-323 [PMID: 19032576 DOI: 10.1111/j.1530-0277.2008.00835.x]  72 **Cuadrado A**, Fábrega E, Casafont F, Pons-Romero F. Alcohol recidivism impairs long-term patient survival after orthotopic liver transplantation for alcoholic liver disease. *Liver Transpl* 2005; **11**: 420-426 [PMID: 15776421 DOI: 10.1002/lt.20386]  73 **Schmeding M**, Neumann UP. Liver Transplant for Cholangiocarcinoma: A Comeback? *Exp Clin Transplant* 2015; **13**: 301-308 [PMID: 26295179]  74 **Erard-Poinsot D**, Guillaud O, Hervieu V, Thimonier E, Vallin M, Chambon-Augoyard C, Boillot O, Scoazec JY, Dumortier J. Severe alcoholic relapse after liver transplantation: What consequences on the graft? A study based on liver biopsies analysis. *Liver Transpl* 2016; **22**: 773-784 [PMID: 26929100 DOI: 10.1002/lt.24425]  75 **Laish I**, Braun M, Mor E, Sulkes J, Harif Y, Ben Ari Z. Metabolic syndrome in liver transplant recipients: prevalence, risk factors, and association with cardiovascular events. *Liver Transpl* 2011; **17**: 15-22 [PMID: 21254340 DOI: 10.1002/lt.22198]  76 **Dumortier J**, Dharancy S, Cannesson A, Lassailly G, Rolland B, Pruvot FR, Boillot O, Faure S, Guillaud O, Rigole-Donnadieu H, Herrero A, Scoazec JY, Mathurin P, Pageaux GP. Recurrent alcoholic cirrhosis in severe alcoholic relapse after liver transplantation: a frequent and serious complication. *Am J Gastroenterol* 2015; **110**: 1160-116; quiz 1167 [PMID: 26169514 DOI: 10.1038/ajg.2015.204]  77 **DiMartini A**, Dew MA, Day N, Fitzgerald MG, Jones BL, deVera ME, Fontes P. Trajectories of alcohol consumption following liver transplantation. *Am J Transplant* 2010; **10**: 2305-2312 [PMID: 20726963 DOI: 10.1111/j.1600-6143.2010.03232.x]  78 **Coffman KL**, Hoffman A, Sher L, Rojter S, Vierling J, Makowka L. Treatment of the postoperative alcoholic liver transplant recipient with other addictions. *Liver Transpl Surg* 1997; **3**: 322-327 [PMID: 9346758 DOI: 10.1002/lt.500030320]  **P-Reviewer:** Keller F, Salvadori M **S-Editor:** Qi Y **L-Editor: E-Editor:** | | |  |  | |  |  |  | | --- | --- | |  | | |  |  | |

**Table 1 Definitions of alcohol use after liver transplantation**

|  |  |  |
| --- | --- | --- |
| **Study** | **Term** | **Definition** |
| Lucey *et al* | Harmful drinking | Consumption of 4 or more drinks in one day or drinking for 4 or more days in succession |
|  | Occasional slip | Consumption of a limited amount of alcohol, followed by immediate procedures to re-establish abstinence |
| De Gottardi *et al* | Harmful drinking | Consumption greater than 40 grams per day that is associated with the presence of alcohol-related damage, such as histologic features of alcoholic liver injury on biopsy |
| Diagnostic and Statistical Manual of Mental Disorders Version IV | Alcohol abuse | Meeting one of the following criteria during a 12 mo period: Use which causes failure to fulfill major role obligations at work, school or home, use which causes a hazardous situation, use which causes legal problems or use continuing in the setting of recurrent social or interpersonal problems |
| World Health Organization | Occasional consumption | Men: < 20 grams per day  Women: < 30 grams per day |
|  | Excessive consumption | Men: > 20 grams per day  Women: > 30 grams per day |

**Table 2 Risk factors associated with alcohol relapse**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Risk Factor** | **Study** | **Study design** | **Sample size** | **Results** |
| Abstinence less than 6 months pre-LT | Perney (2005) | Retrospective | *n* = 61 | Associated with severe relapse to heavy drinking1 |
|  | De Gottardi (2007) | Retrospective | *n* = 387 | Associated with relapse |
|  | Pfitzmann (2007) | Retrospective | *n* = 300 | Associated with relapse |
|  | Tandon (2009) | Retrospective | *n* = 171 | For every 1-mo increment increase in pre-transplant abstinence, there was a 5% decrease in the adjusted relapse rate. |
|  | Karim (2010) | Retrospective | *n* = 80 | Associated with relapse and is an independent risk factor for relapse |
|  | Satapathay (2015) | Retrospective | *n* = 148 | Associated with alcohol relapse |
|  | Osorio (1994) | Retrospective | *n* = 43 | No association |
|  | Jauhar (2004) | Retrospective | *n* = 112 | No association |
|  | Bjornsson (2005) | Retrospective | *n* = 103 | No association |
|  | Addolorato (2013) | Retrospective | *n* = 55 | No association |
|  | Egawa (2014) | Retrospective | *n* = 140 | No association |
| Abstinence < 1 year pre-LT | Kelly (2006) | Retrospective | *n* = 100 | No association with harmful relapse2 |
|  | Gedaly (2008) | Retrospective | *n* = 142 | Independent predictor of relapse |

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Age | Perney (2005) | Retrospective | *n* = 61 | Alcohol relapse group was younger compared to the non-relapse group |
|  | Pfitzmann (2007) | Retrospective | *n* = 300 | Age < 40 years of age was associated with relapse, but was not an independent risk factor. |
|  | Karim (2010) | Retrospective | *n* = 80 | Age < 50 years of age approached clinical significance for alcohol relapse |
|  | Rice (2013) | Retrospective | *n* = 300 | Alcohol relapse group was younger compared to the non-relapse group |
|  | Grat (2014) | Retrospective | *n* = 97 | Younger age < 45 associated with relapse |
|  | Satapathay (2015) | Retrospective | *n* = 148 | Older patients had lower likelihood of alcohol relapse |
|  | De Gottardi (2007) | Retrospective | *n* = 387 | Age >50 years associated with relapse |
|  | Jauhar (2004) | Retrospective | *n* = 112 | No association |
|  | Bjornsson (2005) | Retrospective | *n* = 103 | No association |

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Social Support | Kelly (2006) | Retrospective | *n* = 100 | Lack of partner associated with harmful alcohol relapse2 |
|  | Pfitzmann (2007) | Retrospective | *n* = 300 | Absence of life companion associated with increased risk of alcohol relapse |
|  | DiMartini (2006) | Prospective | *n* = 167 | Marriage is protective against binge use |
|  | Rodrigue (2013) | Retrospective | *n* = 118 | Limited social support associated with alcohol relapse |
|  | Egawa (2014) | Retrospective | *n* = 140 | Marital status associated with alcohol relapse and harmful relapse3 |
|  | Satapathay (2015) | Retrospective | *n* = 148 | Support from immediate family (spouse, parent or child) was highly correlated with reduced risk of alcohol relapse |
| Marital status | Bjornsson (2005) | Retrospective | *n* = 103 | No association |

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Psychiatric Condition | De Gottardi (2007) | Retrospective | *n* = 387 | Associated with relapse |
|  | Karim (2010) | Retrospective | *n* = 80 | Associated with relapse |
|  | Kelly (2006) | Retrospective | *n* = 100 | Previous diagnosis of a mental illness associated with harmful drinking2 |
|  | DiMartini (2006) | Prospective | *n* = 167 | History of depressive disorder associated with alcohol relapse |
|  | Egawa (2014) | Retrospective | *n* = 140 | A history of treatment for psychological diseases other than alcoholism before LT is associated with risk of alcohol relapse but not harmful drinking3 |
|  | Jauhar (2004) | Retrospective | *n* = 112 | Comorbid psychiatric condition had no association with relapse |

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Employment | Jauhar (2004) | Retrospective | *n* = 112 | No association |
|  | Perney (2005) | Retrospective | *n* = 61 | No association |
|  | Kelly (2006) | Retrospective | *n* = 100 | Previous occupation not associated with harmful drinking |
|  | Egawa (2014) | Retrospective | *n* = 140 | Post-LT occupational status not associated with alcohol relapse |
|  | Satapathay (2015) | Retrospective | *n* = 148 | Employment status at time of transplant was not associated with alcohol relapse |

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Cigarette smoking | Pageaux (2003) | Retrospective | *n* = 128 | Occasional and heavy drinkers were more likely to be cigarette smokers compared to abstinent patients |
|  | Kelly (2006) | Retrospective | *n* = 100 | Median cigarette use per day was higher in harmful alcohol relapse group. |
|  | Rodrigue (2013) | Retrospective | *n* = 118 | Associated with alcohol relapse |
|  | Egawa (2014) | Retrospective | *n* = 140 | Cigarette smoking after LT associated with alcohol relapse |
|  | Satapathay (2015) | Retrospective | *n* = 148 | Active cigarette smoking at time of LT associated with alcohol relapse |

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Non-compliance with clinic visits | Egawa (2014) | Retrospective | *n* = 140 | Associated with alcohol relapse and harmful relapse\*\*\* |

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Pre-LT substance abuse or alcohol treatment | DiMartini (2006) | Prospective | *n* = 167 | Prior alcohol rehabilitation was associated with relapse |
|  | Gedaly (2008) | Retrospective | *n* = 142 | Participation in rehabilitation was associated with relapse |
|  | Jauhar (2004) | Retrospective | *n* = 112 | Substance abuse treatment before LT had no association with relapse |
|  | Bjornsson (2005) | Retrospective | *n* = 103 | No association |

1Alcohol consumption of more than 21 units per week for males and 14 units per week for females; 2Alcohol consumption greater than 140 grams of ethanol per week; 3Alcohol consumption greater than 40 grams per day that was associated with the presence of alcohol-related damage. LT: Liver transplantation.